Trial Profile
A study to evaluate short-term efficacy of adalimumab in Japanese patients with axial spondyloarthritis (SpA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Spondylarthritis
- Focus Therapeutic Use
- 07 Nov 2016 New trial record